

Cristina Guarducci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3944287/publications.pdf>

Version: 2024-02-01

20
papers

566
citations

840585

11
h-index

996849

15
g-index

21
all docs

21
docs citations

21
times ranked

965
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
2	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. <i>Oncotarget</i> , 2016, 7, 68012-68022.	0.8	110
3	Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 38.	2.3	78
4	Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response. <i>Breast Care</i> , 2017, 12, 304-308.	0.8	53
5	Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4870-4882.	3.2	49
6	Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. <i>Oncotarget</i> , 2018, 9, 16389-16399.	0.8	37
7	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. <i>BMC Medicine</i> , 2015, 13, 46.	2.3	27
8	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25
9	TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 5755-5764.	3.2	20
10	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	1.1	17
11	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReND trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	2.2	14
12	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2640.	1.7	8
13	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	1.4	3
14	Efficacy of Fulvestrant According to Duration and Type of Adjuvant Endocrine Treatment, in Metastatic Breast Cancer Patients Enrolled in the Confirm Trial. <i>Annals of Oncology</i> , 2014, 25, i8.	0.6	1
15	Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC). <i>Annals of Oncology</i> , 2015, 26, iii15.	0.6	0
16	Targeting the CDK4/6 Pathway in Breast Cancer. , 2017, , 807-817.		0
17	DNA repair metagene signature as a prognostic and predictive factor in molecular breast cancer subtypes. <i>Journal of Clinical Oncology</i> , 2012, 30, 1012-1012.	0.8	0
18	Abstract S1-01: TransCONFIRM: The correlative analysis of breast tumors from patients with advanced hormone receptor positive disease identifies a genetic signature associated with decreased benefit from single agent fulvestrant. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
19	A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).. Journal of Clinical Oncology, 2018, 36, 570-570.	0.8	0
20	Abstract B16: Mathematical modeling identifies optimum palbociclib dosing schedules for the treatment of estrogen receptor-positive (ER+) breast cancer patients. , 2020, , .		0